Though Gilead Sciences made waves last June with a landmark FDA approval for its twice-yearly HIV preventive Yeztugo (lenacapavir), the first-in-class drug had previously been used as a long-acting ...

The technology, called the Viral-Engineered RNA-based Activation System (VERAS), hijacks the virus's own replication machinery to switch on reporter or therapeutic genes precisely in infected cells.

Viral DNA that is usually dismissed when sequencing the human genome could help to uncover useful information about complex ...

University of Toronto researchers have expanded our understanding of bacterial immunity with the discovery of a new protein ...

The field of molecular epidemiology has brought a transformative perspective to the study of viral infections by integrating molecular data and phylogenetic ...